Corline Biomedical AB (STO:CLBIO)
18.20
-0.10 (-0.55%)
May 22, 2026, 5:11 PM CET
Corline Biomedical AB Revenue
Corline Biomedical AB had revenue of 4.31M SEK in the quarter ending March 31, 2026, with 93.57% growth. This brings the company's revenue in the last twelve months to 10.66M, down -23.45% year-over-year. In the year 2025, Corline Biomedical AB had annual revenue of 8.59M, down -50.29%.
Revenue (ttm)
10.66M
Revenue Growth
-23.45%
P/S Ratio
44.60
Revenue / Employee
888.58K
Employees
12
Market Cap
475.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.59M | -8.69M | -50.29% |
| Dec 31, 2024 | 17.27M | -18.25M | -51.37% |
| Dec 31, 2023 | 35.52M | 2.93M | 8.98% |
| Dec 31, 2022 | 32.59M | 15.40M | 89.55% |
| Dec 31, 2021 | 17.19M | 2.12M | 14.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.21M |
| Sprint Bioscience AB | 153.10M |
| Oncopeptides AB | 83.24M |
| Intervacc AB | 19.07M |
| Xintela AB | 2.28M |
| FluoGuide | 318.79K |
| Infant Bacterial Therapeutics AB | -1.00K |
| Mendus AB | -1.44M |
Corline Biomedical AB News
- 16 days ago - Corline Biomedical AB Quarterly report: Q1 2026 - Filings
- 3 months ago - Corline Biomedical AB Quarterly report: Q4 2025 - Filings
- 3 months ago - Corline Biomedical AB Annual report: Q4 2025 - Filings
- 6 months ago - Corline Biomedical AB Quarterly report: Q3 2025 - Filings
- 9 months ago - Corline Biomedical AB Quarterly report: Q2 2025 - Filings